IJROBP Journal SA-CME activity for July 1, 2021 provides practitioners with knowledge about the emerging use of artificial intelligence in data analysis in radiation oncology.

IJROBP Journal SA-CME activity for June 1, 2021 provides practitioners with with information on selection of appropriate candidates for multifraction SBRT for painful vertebral body metastases.

This journal activity provides practitioners with a review of updates in key treatment approaches, particularly with respect to the role of radiotherapy.

IJROBP Journal SA-CME activity for May 1, 2021 provides practitioners with a modern systematic compilation of normal tissue dose-volume effects reported in SBRT for primary or metastatic hepatic malignancies, with derivation of corresponding NTCP models for multiple grade 2-3 toxicity endpoints.

IJROBP Journal SA-CME activity for April 1, 2021 provides practitioners with the knowledge needed to avoid ORN where possible, and to recognize ORN at its early stages for timely management.

This journal activity provides practitioners with a review of updates in key treatment approaches, particularly with respect to the role of radiotherapy.

IJROBP Journal SA-CME activity for March 15, 2021 provides the clinician with important knowledge on new clinical trials as well as ASTRO practice statements have emerged over the past 5 years that may impact how palliative radiation therapy for bone metastases is used.

IJROBP Journal SA-CME activity for March 1, 2021 provides the clinician with important clinical and pre-clinical context as to the significant technical and procedural facets that must be considered for safe and effective implementation of cardiac radioablation for cardiac arrhythmias.

This journal activity provides practitioners with a review of updates in key treatment approaches, particularly with respect to the role of radiotherapy.

IJROBP Journal SA-CME activity for January 1, 2021 provides practitioners with information to improve the informed consent process for both standard treatment and clinical trial enrollment.